Faculty of 1000 evaluation for Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.

Salvage Treatment ◽

Germ Cell Tumours ◽

Phase 2 ◽

Single Institution ◽

Open Label ◽

Phase 2 Study ◽

Deep Hyperthermia

Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(13)70271-7 ◽

2013 ◽

Vol 14 (9) ◽

pp. 843-852 ◽

Cited By ~ 50

Author(s):

Rüdiger Wessalowski ◽

Dominik T Schneider ◽

Oliver Mils ◽

Verena Friemann ◽

Olga Kyrillopoulou ◽

...

Keyword(s):

Germ Cell ◽

Salvage Treatment ◽

Germ Cell Tumours ◽

Phase 2 ◽

Single Institution ◽

Open Label ◽

Phase 2 Study ◽

Deep Hyperthermia

21 An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumours (GCT): Results at the end of first stage (FM12GCT01)

European Urology Supplements ◽

10.1016/s1569-9056(16)60023-4 ◽

2016 ◽

Vol 15 (3) ◽

pp. e21

Author(s):

A. Necchi ◽

D. Magazzu’ ◽

A. Anichini ◽

D. Raggi ◽

P. Giannatempo ◽

...

Keyword(s):

Germ Cell ◽

Salvage Therapy ◽

Brentuximab Vedotin ◽

Germ Cell Tumours ◽

Phase 2 ◽

Single Group ◽

Open Label ◽

Phase 2 Study

APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

European Urology Supplements ◽

10.1016/s1569-9056(17)30282-8 ◽

2017 ◽

Vol 16 (3) ◽

pp. e373-e374

Author(s):

A. Necchi ◽

L. Mariani ◽

A. Anichini ◽

P. Giannatempo ◽

D. Raggi ◽

...

Keyword(s):

Germ Cell ◽

Germ Cell Tumors ◽

Phase 2 ◽

Open Label ◽

Programmed Death Ligand 1 ◽

Programmed Death ◽

Phase 2 Study ◽

Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.4547 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 4547-4547 ◽

Cited By ~ 4

Author(s):

Daniele Raggi ◽

Patrizia Giannatempo ◽

Luigi Mariani ◽

Maurizio Colecchia ◽

Giuseppina Calareso ◽

...

Keyword(s):

Germ Cell ◽

Germ Cell Tumors ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

[BRIGHT (ZYN2-CL-030)] TOLERABILITY AND EFFICACY OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER: AN OPEN-LABEL PHASE 2 STUDY

Journal of the American Academy of Child & Adolescent Psychiatry ◽

10.1016/j.jaac.2020.08.463 ◽

2020 ◽

Vol 59 (10) ◽

pp. S264-S265

Author(s):

Helen Heussler ◽

Michael Duhig ◽

Terry Hurst ◽

Carol O'Neill ◽

Donna Gutterman ◽

...

Keyword(s):

Autism Spectrum Disorder ◽

Autism Spectrum ◽

Spectrum Disorder ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Adolescents With Autism ◽

Open Label Phase

LONGER-TERM TOLERABILITY AND EFFICACY OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER: AN OPEN-LABEL PHASE 2 STUDY (BRIGHT [ZYN2-CL-030])

Journal of the American Academy of Child & Adolescent Psychiatry ◽

10.1016/j.jaac.2021.09.419 ◽

2021 ◽

Vol 60 (10) ◽

pp. S258

Author(s):

Joseph Palumbo ◽

Helen Heussler ◽

Michael Duhig ◽

Terry Hurst ◽

Carol O'Neill ◽

...

Keyword(s):

Autism Spectrum Disorder ◽

Autism Spectrum ◽

Spectrum Disorder ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Adolescents With Autism ◽

Open Label Phase ◽

Term Tolerability

APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

Annals of Oncology ◽

10.1093/annonc/mdw373.73 ◽

2016 ◽

Vol 27 ◽

pp. vi293 ◽

Cited By ~ 1

Author(s):

A. Necchi ◽

L. Mariani ◽

A. Anichini ◽

P. Giannatempo ◽

D. Raggi ◽

...

Keyword(s):

Germ Cell ◽

Germ Cell Tumors ◽

Phase 2 ◽

Open Label ◽

Programmed Death Ligand 1 ◽

Programmed Death ◽

Phase 2 Study ◽

1123 Activity of pazopanib in chemoresistant patients with germ cell tumours (GCT): Early findings of the open-label, single-group, phase 2 pazotest-01 trial

European Urology Supplements ◽

10.1016/s1569-9056(14)61103-9 ◽

2014 ◽

Vol 13 (1) ◽

pp. e1123

Author(s):

A. Necchi ◽

L. Mariani ◽

P. Giannatempo ◽

N. Nicolai ◽

E. Farè ◽

...

Keyword(s):

Germ Cell ◽

Germ Cell Tumours ◽

Phase 2 ◽

Single Group ◽

Open Label

An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis

European Urology ◽

10.1016/j.eururo.2018.09.010 ◽

2019 ◽

Vol 75 (1) ◽

pp. 201-203 ◽

Cited By ~ 24

Author(s):

Andrea Necchi ◽

Patrizia Giannatempo ◽

Daniele Raggi ◽

Luigi Mariani ◽

Maurizio Colecchia ◽

...

Keyword(s):

Germ Cell ◽

Interim Analysis ◽

Germ Cell Tumors ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.11 ◽

2017 ◽

Vol 1 ◽

pp. s12

Author(s):

Andrew Blauvelt ◽

Craig Leonardi ◽

Claus Zachariae ◽

Russel Burge ◽

Terri Ridenour ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 2 ◽

Chronic Plaque Psoriasis ◽

Open Label ◽

Phase 2 Study ◽

Health Related

Abstract Not Available